Awaiting price reaction for this filing.
JB Pharma reported Q4 FY25 revenue of INR 949 crores, up 10% YoY, with net profit rising 15% to INR 146 crores. Operating EBITDA grew 15% to INR 240 crores, with margins improving 90 basis points to 25.3%. For the full year FY25, revenue rose 12% to INR 3,918 crores, operating EBITDA crossed INR 1,000 crores for the first time at INR 1,087 crores (up 16%), and net profit grew 19% to INR 660 crores. The domestic formulations business was the standout performer, growing 20% to INR 2,269 crores for the year, while CDMO bounced back with 18% growth in Q4. The company strengthened its balance sheet significantly, moving to a net cash position of INR 689 crores (vs INR 107 crores in FY24) and improving ROCE to 32% from 27%.
Strong, broad-based growth across both domestic and CDMO segments with margin expansion, robust cash generation, and an improving return profile is positive for shareholders. The company trades at a premium valuation that is being supported by consistent execution and the shift towards higher-margin businesses.